Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills
Reexamination Certificate
2005-10-06
2010-10-26
Wax, Robert A (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Tablets, lozenges, or pills
C424S474000, C424S480000
Reexamination Certificate
active
07820199
ABSTRACT:
A film-coated extended release solid oral dosage composition containing a nasal decongestant, pseudoephedrine or salt thereof, e.g., pseudoephedrine sulfate in a core effective to provide a geometric maximum plasma concentration of pseudoephedrine of about 345 ng/mL to about 365 ng/mL at a time of about 7.60 hrs to about 8.40 hrs and having two or three film-coatings on the core, the second one containing an amount of the non-sedating antihistamine, desloratadine, effective to provide a geometric maximum plasma concentration of desloratadine of about 2.15 ng/mL to about 2.45 ng/mL at a time of about 4.0 hours to about 4.5 hours, and use of the composition for treating patients showing the signs and symptoms associated with allergic and/or inflammatory conditions of the skin and airway passages are disclosed.
REFERENCES:
patent: 3536809 (1970-10-01), Applezweig
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 3940485 (1976-02-01), Levinson et al.
patent: 4008796 (1977-02-01), Aylon
patent: 4282233 (1981-08-01), Vilani
patent: 4371516 (1983-02-01), Gregory et al.
patent: 4552899 (1985-11-01), Sunshine et al.
patent: 4659716 (1987-04-01), Villani et al.
patent: 4731447 (1988-03-01), Schumacher et al.
patent: 4777170 (1988-10-01), Heinrich
patent: 4783465 (1988-11-01), Sunshine et al.
patent: 4804666 (1989-02-01), Piwinski et al.
patent: 4863931 (1989-09-01), Schumacher et al.
patent: 4906647 (1990-03-01), Kouchiwa et al.
patent: 4917900 (1990-04-01), Jones et al.
patent: 4990535 (1991-02-01), Cho et al.
patent: 5019591 (1991-05-01), Gardner et al.
patent: 5089496 (1992-02-01), Piwinski et al.
patent: 5100675 (1992-03-01), Cho et al.
patent: 5314697 (1994-05-01), Kwan et al.
patent: 5407941 (1995-04-01), Carceller et al.
patent: 5476856 (1995-12-01), Carceller et al.
patent: 5487901 (1996-01-01), Conte et al.
patent: 5508042 (1996-04-01), Oshlack et al.
patent: 5595997 (1997-01-01), Aberg et al.
patent: 5731319 (1998-03-01), Aberg et al.
patent: 5807579 (1998-09-01), Vilkov et al.
patent: 5900421 (1999-05-01), Handley et al.
patent: 5939426 (1999-08-01), McCullough
patent: 5962464 (1999-10-01), Handley et al.
patent: 5997903 (1999-12-01), Dietrich et al.
patent: 6051585 (2000-04-01), Weinstein et al.
patent: 6100274 (2000-08-01), Kou
patent: 6114346 (2000-09-01), Harris
patent: 6132758 (2000-10-01), Munayyer et al.
patent: 6270796 (2001-08-01), Weinstein et al.
patent: 6372802 (2002-04-01), Hellberg et al.
patent: 6423721 (2002-07-01), Harris et al.
patent: 6432972 (2002-08-01), Salmun et al.
patent: 6506767 (2003-01-01), Schumacher et al.
patent: 6514520 (2003-02-01), Munayyer et al.
patent: 6521254 (2003-02-01), Weinstein et al.
patent: 6599913 (2003-07-01), Johnson et al.
patent: 6709676 (2004-03-01), Cho
patent: 7405223 (2008-07-01), Affrime et al.
patent: 7618649 (2009-11-01), Cho
patent: 2004/0097536 (2004-05-01), Cho
patent: 0 264 259 (1988-04-01), None
patent: 0 288640 (1988-11-01), None
patent: 0173928 (1990-06-01), None
patent: 0 396404 (1990-11-01), None
patent: 0 577 957 (1994-01-01), None
patent: 0 396404 (1994-02-01), None
patent: 0655744 (2000-01-01), None
patent: 1112738 (2001-07-01), None
patent: WO 85/03707 (1985-08-01), None
patent: WO 92/00293 (1992-01-01), None
patent: WO 92/11034 (1992-07-01), None
patent: WO 92/20377 (1992-11-01), None
patent: WO-94/09761 (1994-05-01), None
patent: WO 96/16641 (1996-06-01), None
patent: WO 96/20708 (1996-07-01), None
patent: WO 98/34614 (1998-08-01), None
patent: WO 00/02560 (2000-01-01), None
Cardelus et al., “Anticholinergic effects of desloratadine, the major metabolite of loratadine, in rabbit and guinea-pig iris smooth muscle”, European Journal of Pharmacology, 374:249-254, 1999.
Kosoglou et al., “Pharmacokinetics of Loratadine and Pseudoephedrine Following Single and Multiple Doses of Once-Versus Twice-Daily Combination Tablet Formulations in Healthy Adult Males” Clinical Therapeutics, 19(5):1002-1012, 1997.
Kreutner et al., “Preclinical Pharmacology of Desloratadine, a Selective and Nonsedating Histamine H1, Receptor Antagonist. 2nd Communication: Lack of central nervous system and cardiovascular effects” Arzneimittel-Forschung/Drug Res., 50(5):441-448, 2000.
Nomeir et al., “Influence of Food on the Oral Bioavailability of Loratadine and Pseudoephedrine from Extended-Release Tablets in Healthy Volunteers” J. Clin Pharmacology, 36:923-930, 1996.
Connors, et al., Chemical Stability of Pharmaceuticals, a Handbook for Pharmacists, 135-159 (John Wiley & Sons 1986).
Technology of Drug Forms, Educational Literature for Students of Pharmaceutical Institutes, vol. 2, 134, 187, 188, 189 (L.A. Ivanova, ed.) (Moscow, “Meditsina” 1991).
Food and Drug Administration / Center for Drug Evaluation and Research, Guidance for Industry—Q3B Impurities in New Drug Products (Nov. 1997).
Food and Drug Administration / Center for Drug Evaluation and Research, Guidance for Industry—Dissolution Testing of Immediate Release Solid Oral Dosage Forms (Aug. 1997).
Food and Drug Administration / Center for Drug Evaluation and Research, Guidance for Industry—SUPAC-MR: Modified Release Solid Oral Dosage Forms, Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation (Sep. 1997).
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline—Impurities in New Drug Products Q3B(R2), Current Step 4 Version (Jun. 2, 2006).
USP 30 / NF 25, vol. 1, 277-284 (2007).
Andersen, et al., “Adverse drug interactions clinically important for the dermatologist”, Arch Dermatol, Apr. 1995, vol. 131, pp. 468-473.
Babe, et al., “Histamine, Bradykinn, and their Antagonists” in The Pharmacological Basis of Therapeutics (9thedition), The McGraw-Hill Co. Inc., pp. 581-599 (1996).
Barnett, et al.,“Pharmacology of Non-Sedating H1 Antihistamines”New Perspectives in Histamine Research, Birkhauser Verlag Basel, pp. 181-196 (1991).
Berge, et al., “Pharmaceutical Salts”, J. of Pharm. Sciences, Jan. 1977, vol. 66, No. 1, pp. 1-19.
Berthon, et al., “In Vitro inhibition, by loratadine and descarboxyethoxyloratadine, of histamine release from human basophils, and of histamine release and intracellular calcium fluxes in rat basophilic leukemia cells (RBL-2H3)”, Biochem. Pharm., 1994, vol. 47, No. 5, pp. 789-794.
Blaug, et al., “Interaction of dextroamphetamine sulfate with spray-dried lactose”, J. of Pharm. Sciences, Nov. 1972, vol. 61, No. 11, pp. 1770-1775.
Brandes, et al., “Enhanced cancer growth in mice administered daily human-equivalent doses of some H1-antihistamines: predictive in vitro correlates”, J. of the National Cancer Inst., May 18, 1994, vol. 86, No. 10, pp. 770-775.
Brandes, et al., “Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses”, Cancer Research, Jul. 1, 1992, vol. 52, pp. 3796-3800.
Brion, et al., “Evaluation of the antimuscarinic activity of atropine, terfenadine and mequitazine in healthy volunteers”, Br. J. Clin. Pharmac. 1988, vol. 25, pp. 27-32.
Carmeliet, “Voltage- and Time-Dependent Block of the Delayed K+ Current in Cardiac Myocytes by Dofetilide”, The J. of Pharm. And Experimental Therapeutics, 1992, vol. 262, No. 2, pp. 809-817.
Castello, et al., “Discoloration of tablets containing amines and lactose”, J. of Pharm. Sciences, Feb. 1962, vol. 51, No. 2, pp. 106-108.
Cheung, et al., “Investigation of anti-motion sickness drugs in the squirrel monkey”, J. Clin. Pharmacol, 1992, vol. No. 32, pp. 163-175.
Clissold, et al., “Loratadine: A preliminary review of its pharmacodynamic properties and therapeutic efficacy”, Drugs, 1989,vol. 37, pp. 42-57.
Cooke, “Glycop
Jacobsen Barry H.
Mercier Melissa S
Schering Corporation
Wax Robert A
LandOfFree
Stable extended release oral dosage composition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Stable extended release oral dosage composition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stable extended release oral dosage composition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4186904